Health Catalyst, Inc. (HCAT): who owns it and who trades it
As of Nov 16, 2026, HCAT insiders reported 4 open-market sales worth $342K and 1 purchase worth $106K in the last 12 months, with 41% of the sale value made under pre-set 10b5-1 plans. The largest seller was Benjamin Landry (General Counsel), with $213K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Health Catalyst
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns HCAT
126 funds and institutions reported HCAT shares worth $105M at the end of Q2 2026, about 72% of the company. The largest holder is First Light Asset Management, LLC with 17.4%.
Funds and institutions (13F) 72%Everyone else 28%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| First Light Asset Management, LLC | 12.81M | 17.41% | $25.5M | -1% |
| CDC Financial, Inc. | 7.09M | 9.64% | $14.1M | +12% |
| Palogic Value Management, L.P. | 4.92M | 6.69% | $9.8M | +70% |
| Impax Asset Management Group plc | 4.00M | 5.44% | $8M | +45% |
| Nepsis Inc. | 2.98M | 4.04% | $5.9M | +59% |
| Vanguard Capital Management LLC | 2.97M | 4.04% | $5.9M | +3% |
| BlackRock, Inc. | 1.84M | 2.50% | $3.7M | -64% |
| Jane Street Group, LLC | 1.04M | 1.41% | $2.1M | +3806% |
| Dimensional Fund Advisors LP | 911,819 | 1.24% | $1.8M | -26% |
| Geode Capital Management, LLC | 891,357 | 1.21% | $1.8M | -41% |
| HighMark Wealth Management LLC | 871,082 | 1.18% | $1.7M | -4% |
| Caption Management, LLC | 773,650 | 1.05% | $1.5M | +0% |
| Mink Brook Asset Management LLC | 738,277 | 1.00% | $1.5M | – |
| Prescott Group Capital Management, L.L.C. | 710,803 | 0.97% | $1.4M | No change |
| Charles Schwab Investment Management Inc | 615,504 | 0.84% | $1.2M | +1% |
| Sixth Street Partners Management Company, L.P. | 615,504 | 0.84% | $1.2M | – |
| Hrt Financial LP | 572,215 | 0.78% | $1.1M | +135% |
| Millennium Management LLC | 516,083 | 0.70% | $1M | – |
| Goldman Sachs Group Inc | 480,970 | 0.65% | $957K | +24% |
| Vanguard Fiduciary Trust Co | 463,005 | 0.63% | $921K | +4% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, HCAT insiders reported $106K of open-market purchases and $342K of sales. 41% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Benjamin Landry | General Counsel | Sale plan | 29,478 | $1.39 | $41K | Form 4 |
| Nov 11, 2026 | Benjamin Landry | General Counsel | Sale plan | 70,000 | $1.43 | $100K | Form 4 |
| Sep 14, 2026 | Simeon Kohl | CEO | Purchase | 59,000 | $1.79 | $106K | Form 4 |
| Dec 5, 2025 | Benjamin Landry | General Counsel | Sale | 27,425 | $2.64 | $72.4K | Form 4 |
| Dec 4, 2025 | Julie Larson-Green | Director | Sale | 47,997 | $2.67 | $128K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Benjamin Landry | General Counsel | – | $213K | Nov 12, 2026 |
| Julie Larson-Green | Director | – | $128K | Dec 4, 2025 |
| Simeon Kohl | Chief Executive Officer, Director | $106K | – | Sep 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HCAT short interest
Low short interest. 2.6% of HCAT shares are sold short: about 1 share in 39. Over the last 12 reports the number of shares short went down 73%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.95M HCAT shares were sold short, 2.6% of the shares outstanding, down 5.6% from the report before. At the average daily volume of 271,857 shares, buying them all back would take about 7.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.95M | 2.59% | -6% | 271,857 | 7.2 |
| Oct 15, 2026 | 2.07M | 2.75% | -7% | 473,737 | 4.4 |
| Sep 30, 2026 | 2.21M | 2.94% | +9% | 425,909 | 5.2 |
| Sep 15, 2026 | 2.03M | 2.70% | +4% | 516,664 | 3.9 |
| Aug 31, 2026 | 1.95M | 2.59% | -15% | 477,347 | 4.1 |
| Aug 14, 2026 | 2.29M | 3.04% | -23% | 1.40M | 1.6 |
| Jul 31, 2026 | 2.99M | 3.97% | -18% | 493,067 | 6.1 |
| Jul 15, 2026 | 3.65M | 4.95% | -21% | 965,372 | 3.8 |
| Jun 30, 2026 | 4.60M | 6.25% | -28% | 2.17M | 2.1 |
| Jun 15, 2026 | 6.35M | 8.63% | -4% | 4.07M | 1.6 |
| May 29, 2026 | 6.59M | 8.95% | -9% | 531,628 | 12.4 |
| May 15, 2026 | 7.21M | 9.80% | -5% | 643,628 | 11.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Health Catalyst company events
Health Catalyst filed 15 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 14, 2026LeadershipTami Reller was appointed to the Board, following the recommendation of the Nominating and Corporate Governance Committee of the Board (the Nominating Committee), to serve as a Class III director until her successor is duly elected and qualified, or until her earlier resignation, death or removal. Filing
- Sep 8, 2026LeadershipThe Board of Directors (the Board) of Health Catalyst, Inc. (the Company) appointed Simeon Kohl to succeed Ben Albert as the Company’s Chief Executive Officer, President, principal executive officer and principal operating officer and, upon the recommendation of the Nominating and Corporate… Filing
- Aug 6, 2026DealBelow) together with cash on hand, voluntarily repaid in full all outstanding obligations under that certain credit facility governed by that certain Credit Agreement, dated as of July 16, 2024, among Health Catalyst, as the borrower, the several lenders party thereto, and Silver Point Finance… Filing
- Jul 20, 2026VoteReported shareholder vote results. Filing
- Jun 4, 2026AgreementHealth Catalyst, Inc. entered into a Unit Purchase Agreement with Med-Metrix, LLC, pursuant to which, among other things, Health Catalyst has agreed to sell all of the equity interests of Vitalware, LLC, through which Health Catalyst conducts its Vitalware business, to Buyer. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Apr 30, 2026LeadershipThe board of directors (our Board) of Health Catalyst, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Steven Nelson to the Board, effective May 1, 2026. Filing
- Apr 27, 2026LeadershipThe Board of Directors (our Board) of Health Catalyst, Inc. (the Company) determined that Linda Llewelyn will cease to serve as the Chief People Officer of the Company effective June 1, 2026 due to the elimination of the Chief People Officer role in connection with the workforce reduction described… Filing
- Apr 3, 2026LeadershipAs previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on February 18, 2026, on February 12, 2026, Daniel Burton informed the Board of Directors of Health Catalyst, Inc. (the Company) of the acceleration of the effective date of his retirement from… Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Feb 18, 2026LeadershipThe Board of Directors (the Board) of Health Catalyst, Inc. (the Company) appointed Ben Albert to succeed Mr. Burton as the Company’s Chief Executive Officer and principal executive officer, effective February 12, 2026. Filing
- Jan 23, 2026LeadershipThe Board of Directors of Health Catalyst, Inc. (the Company) determined that Kevin Freeman will cease to serve as the Chief Commercial Officer of the Company on February 1, 2026. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 2, 2025LeadershipOf this Current Report on Form 8-K, on December 1, 2025, the Company, First Light Asset Management, LLC and Mr. Arens entered into a letter agreement, pursuant to which First Light and Mr. Arens have agreed to abide by certain voting and confidentiality commitments that will remain in effect until… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Health Catalyst financials
Famous investors that hold HCAT
4 of the 50 well-known investors we track reported holding HCAT in their latest 13F filing. The largest position is Israel Englander's, worth $462K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 267,287 | $462K | 0.0% | -48% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 215,206 | $372K | 0.0% | -53% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 79,600 | $138K | 0.0% | -77% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 19,929 | $34.5K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Health Catalyst, Inc. (HCAT) stock
Who owns the most HCAT stock?
The largest reported owner of Health Catalyst, Inc. (HCAT) is First Light Asset Management, LLC, with 17.4% of the company. In total, 126 funds and institutions reported holding HCAT at the end of Q2 2026, together about 72% of the shares. See the largest owners.
Are HCAT insiders buying or selling?
In the last 12 months, HCAT insiders reported 1 open-market purchase worth $106K and 4 sales worth $342K. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in HCAT?
As of Oct 30, 2026, 1.95M HCAT shares were sold short, 2.6% of the shares outstanding, down 5.6% from the report before. At the average daily volume of 271,857 shares, buying them all back would take about 7.2 trading days (days to cover). See the history.
Which famous investors hold HCAT?
4 of the 50 well-known investors we track reported HCAT in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $462K. See all holders.
Executive pay
Health Catalyst's chief executive was paid a total of $4M for the year ended Dec 31, 2025, down 27% from $5.5M the year before. In the last 12 months, Health Catalyst's executives and directors bought $106K of stock on the open market and sold $342K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.